Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ

U. E. Studer, G. Casanova, R. Kraft, E. J. Zingg, D. L. Lamm, M. S. Soloway

Research output: Contribution to journalArticle

88 Scopus citations

Abstract

Ten pyeloureteral systems in 8 patients (mean age 74 years) with cytologically proved ureteral carcinoma in situ (1 combined with ureteral papillary tumors) were perfused with bacillus Calmette-Guerin via a percutaneous nephrostomy tube. In 4 patients cytology results remained negative after 1 treatment course during an observation time of 18 to 28 months. In 1 patient a papillary tumor persisted with cytology results became negative for carcinoma in situ. Two patients with bilateral disease had repeated perfusion of bacillus Calmette-Guerin until cytology results became negative and they remained negative during observation for 18 months in 1. The other patient had a multifocal recurrence of carcinoma in situ, combined with a stage T1, grade 3 urothelial cancer in the bladder after 12 months and a recurrence of carcinoma in situ in 1 ureter after 24 months. In 1 patient treatment was stopped prematurely after severe septicemia. Although our short-term results are promising, percutaneous perfusion of bacillus Calmette-Guerin for carcinoma in situ of the upper urinary tract should be considered as an investigational treatment modality until long-term results are available.

Original languageEnglish (US)
Pages (from-to)975-977
Number of pages3
JournalJournal of Urology
Volume142
Issue number4
DOIs
StatePublished - Jan 1 1989

    Fingerprint

ASJC Scopus subject areas

  • Urology

Cite this

Studer, U. E., Casanova, G., Kraft, R., Zingg, E. J., Lamm, D. L., & Soloway, M. S. (1989). Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ. Journal of Urology, 142(4), 975-977. https://doi.org/10.1016/S0022-5347(17)38957-7